Paul L. Nguyen, MD, of Dana-Farber Cancer Institute, discusses this phase III trial in which prostate cancer patients were given antiandrogen therapy with bicalutamide during and after salvage radiation therapy following radical prostatectomy and an elevated PSA (Abstract 3).
Maha Hussain, MD, of the University of Michigan, gives her expert perspective on changes in the treatment of hormone-naive disease.
Bishoy M. Faltas, MD, of Weill Cornell Medical College, discusses his team’s work using whole exome sequencing, which may have important implications for selecting patients for immunotherapeutic approaches (Abstract 354).
Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses the best use of approved therapies for tumors that have spread to the bone.
A. Oliver Sartor, MD, of Tulane Cancer Center, discusses this study investigating circulating tumor cell characteristics to predict resistance to androgen deprivation therapies in patients with advanced prostate cancer (Abstract 163).
W. Robert Lee, MD, of Duke University, discusses this phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract 1).
